Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-02-15
|
Aranesp® (darbepoetin alfa) |
anemic patients with low and intermediate-1 risk myelodysplastic syndrome (MDS) |
3 |
Amgen (USA - CA) |
Cancer - Oncology |
2016-02-14
|
JHL1101 (biosimilar version of rituximab) |
rheumatoid arthritis |
3 |
JHL Biotech (Taiwan) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2016-02-13
|
liraglutide |
NASH (non-alcoholic steatohepatitis) |
2 |
Novo Nordisk (Denmark) |
Hepatic diseases - Liver diseases |
2016-02-12
|
pembrolizumab (MK-3475) |
Hodgkin lymphoma |
3 |
Merck&Co (USA - NJ) |
Cancer - Oncology |
2016-02-12
|
CLBS03 |
diabetes |
2 |
Caladrius Biosciences (USA - CA) |
Metabolic diseases |
2016-02-11
|
elafibranor - GFT505 |
NASH (non-alcoholic steatohepatitis) |
2b |
Genfit (France) |
Metabolic diseases - Liver diseases |
2016-02-11
|
ruxolitinib and capecitabine |
metastatic pancreatic cancer |
3 |
Incyte (USA - DE) |
Cancer - Oncology |
2016-02-10
|
ALLN-177 |
secondary hyperoxaluria |
2 |
Allena Pharmaceuticals (USA - MA) |
Kidney diseases - Renal diseases |
2016-02-10
|
Accurins™ |
|
preclinical |
Bind Therapeutics (USA - MA) |
Cancer - Oncology |
2016-02-10
|
elagolix |
endometriosis |
3 |
Abbvie (USA - IL) Neurocrine Biosciences (USA - CA) |
Women health |
2016-02-10
|
IMMray™systemic lupus erythematosus biomarker signatures |
systemic lupus erythematosus (SLE) |
|
Immunovia (Sweden) Lund University (Sweden) |
Autoimmune diseases |
2016-02-10
|
HTL9936 |
Alzheimer’s disease and other diseases associated with dementia and cognitive impairment |
1b |
Heptares Therapeutics (UK), a wholly-owned subsidiary of Sosei Group (Japan) |
Neurodegenerative diseases |
2016-02-09
|
CAR-T cell therapy modified using the Sleeping Beauty system |
advanced lymphoid malignancies |
1 |
Ziopharm Oncology (USA - MA) |
Cancer - Oncology |
2016-02-09
|
remimazolam |
general anesthesia |
3 |
Paion (Germany) |
CNS diseases |
2016-02-09
|
4Kscore® Test |
prostate cancer |
|
Opko Health (USA - Fl) |
Cancer - Oncology |
2016-02-08
|
PM1183 plus doxorubicin |
ovarian cancer |
3 |
PharmaMar (Spain) |
Cancer - Oncology |
2016-02-07
|
Mast Cell Connect patient registry |
mastocytosis |
|
Blueprint Medicines (USA - MA) PatientCrossroads (USA - CA) |
Rare diseases - Hematological diseases |
2016-02-05
|
Blincyto® (blinatumomab) |
Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) |
3 |
Amgen (USA - CA) |
Cancer - Oncology |
2016-02-05
|
AG-120 - isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor, AG-221 (enasidenib) and subcutaneous azacitidine |
acute myeloid leukemia (AML) |
1-2 |
Celgene (USA - NJ) |
Cancer - Oncology |
2016-02-04
|
MYK-461 |
hypertrophic cardiomyopathy |
preclinical |
Myokardia (USA - CA) |
Cardiovascular diseases |